{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:53:35Z","timestamp":1781276015063,"version":"3.54.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,27]],"date-time":"2018-01-27T00:00:00Z","timestamp":1517011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,1,27]],"date-time":"2018-01-27T00:00:00Z","timestamp":1517011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s40268-018-0227-y","type":"journal-article","created":{"date-parts":[[2018,1,27]],"date-time":"2018-01-27T07:12:25Z","timestamp":1517037145000},"page":"87-90","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["In Vitro Safety Pharmacology Profiling of Topical \u03b1-Adrenergic Agonist Treatments for Erythema of Rosacea"],"prefix":"10.1007","volume":"18","author":[{"given":"David","family":"Piwnica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Docherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,27]]},"reference":[{"issue":"3","key":"227_CR1","first-page":"26","volume":"5","author":"JQ Del Rosso","year":"2012","unstructured":"Del Rosso JQ. Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea. J Clin Aesthet Dermatol. 2012;5(3):26\u201336.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"227_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bjd.15122","volume":"176","author":"J Tan","year":"2017","unstructured":"Tan J, Almeida LM, Bewley A, Cribier B, Dlova NC, Gallo R, Kautz G, Mannis M, Oon HH, Rajagopalan M, Steinhoff M, Thiboutot D, Troielli P, Webster G, Wu Y, van Zuuren EJ, Schaller M. Updating the diagnosis, classification and assessment of rosacea recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):431\u20138.","journal-title":"Br J Dermatol"},{"issue":"17","key":"227_CR3","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1001\/jama.1993.03500170088039","volume":"269","author":"MB Smith","year":"1993","unstructured":"Smith MB, Feldman W. Over-the-counter cold medications. A critical review of clinical trials between 1950 and 1991. JAMA. 1993;269(17):2258\u201363 (review).","journal-title":"JAMA"},{"key":"227_CR4","first-page":"CD009612","volume":"10","author":"L Deckx","year":"2016","unstructured":"Deckx L, De Sutter AI, Guo L, Mir NA, van Driel ML. Nasal decongestants in monotherapy for the common cold. Cochrane Database Syst Rev. 2016;10:CD009612 (review).","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"227_CR5","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1517\/14656566.1.4.815","volume":"1","author":"LB Cantor","year":"2000","unstructured":"Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother. 2000;1(4):815\u201334 (review).","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"227_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jdermsci.2014.04.002","volume":"75","author":"D Piwnica","year":"2014","unstructured":"Piwnica D, Rosignoli C, de M\u00e9nonville ST, Alvarez T, Schuppli Nollet M, Roye O, Jomard A, Aubert J. Vasoconstriction and anti-inflammatory properties of the selective \u03b1-adrenergic receptor agonist brimonidine. J Dermatol Sci. 2014;75(1):49\u201354.","journal-title":"J Dermatol Sci"},{"issue":"6","key":"227_CR7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","volume":"63","author":"V Setola","year":"2003","unstructured":"Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL. 3,4-Methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol. 2003;63(6):1223\u20139.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"227_CR8","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1124\/mol.109.058057","volume":"76","author":"XP Huang","year":"2009","unstructured":"Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M, Doucette C, Roth BL. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol. 2009;76(4):710\u201322.","journal-title":"Mol Pharmacol"},{"issue":"6","key":"227_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0192623310378027","volume":"38","author":"CS Elangbam","year":"2010","unstructured":"Elangbam CS. Drug-induced valvulopathy: an update. Toxicol Pathol. 2010;38(6):837\u201348.","journal-title":"Toxicol Pathol"},{"issue":"1","key":"227_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1056\/NEJMp068265","volume":"356","author":"BL Roth","year":"2007","unstructured":"Roth BL. Drugs and valvular heart disease. N Engl J Med. 2007;356(1):6\u20139.","journal-title":"N Engl J Med"},{"key":"227_CR11","unstructured":"Kuang A, DuBois J, Ahluwalia G, Zhang S. Clinical pharmacokinetics of oxymetazoline cream following topical facial administration for the treatment of erythema associated with rosacea. Poster presentation at American Academy of Dermatology Annual Meeting, March 20\u201324, 2015, San Francisco, CA, USA."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-018-0227-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0227-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0227-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T08:29:07Z","timestamp":1603441747000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-018-0227-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,27]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["227"],"URL":"https:\/\/doi.org\/10.1007\/s40268-018-0227-y","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,27]]},"assertion":[{"value":"27 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was supported by Nestle Skin Health R&D, Sophia Antipolis, France.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"DP and GS are full-time employees of Nestle Skin Health\/Galderma. AP has received consulting fees from Galderma for advisory meetings and manuscript writing and reviewing. JRD has served as an advisory board member for Galderma Laboratories. Galderma markets a brimonidine product for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18\u00a0years of age or older.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}